Education
About Us
Working with TipRanks
Follow Us
ProQR (PRQR)
NASDAQ:PRQR
PRQR Stock Chart & Stats
$1.46
-$0.10(-3.77%)
At close: 4:00 PM EST
$1.46
-$0.10(-3.77%)
Day’s Range― - ―
52-Week Range$1.07 - $3.10
Previous CloseN/A
Volume75.97K
Average Volume (3M)534.76K
Market Cap
$153.80M
Enterprise Value$39.14M
Total Cash (Recent Filing)$106.88M
Total Debt (Recent Filing)$16.49M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Feb 19, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding105,345,190
10 Day Avg. Volume796,312
30 Day Avg. Volume534,757
Financial Highlights & Ratios
PEG Ratio2.63
Price to Book (P/B)2.36
Price to Sales (P/S)11.05
P/FCF Ratio-5.53
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue2.52
Enterprise Value/Gross Profit2.52
Enterprise Value/Ebitda-1.03
Forecast
1Y Price Target
$8.50Price Target Upside482.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Profit MarginA 100% gross profit margin indicates the platform can cover direct product costs and, if commercialized, offer strong unit economics. This durable advantage can support long-term margin recovery as fixed R&D and SG&A scale down versus potential product revenue.
Manageable LeverageA modest debt-to-equity ratio (0.25) gives ProQR financial flexibility and lower refinancing risk compared with highly leveraged peers. This structural balance sheet strength helps sustain funding for multi-year clinical programs without immediate pressure to service large debt loads.
Pipeline Progress And Partnership FundingPositive Phase 1 safety/PK data and selection of additional development candidates strengthen the R&D pipeline and de-risk program progression. Material milestone payments from Eli Lilly provide non-dilutive financing, extending runway into mid-2027 and enabling multiple development and partnering paths.
Bears Say
Severe Negative ProfitabilityA trailing net margin of -240% signals structural operating losses far exceeding revenues. Sustained hyper-negative margins indicate the company must achieve clinical and commercial milestones or secure significant external funding to reach breakeven, posing a long-term viability risk.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow constrain internal funding for R&D and operations, increasing reliance on partnerships, milestone payments, or equity/debt financing. This structural cash burn elevates dilution and refinancing risk over the 2–6 month horizon and beyond.
Declining Revenue And Rising Operating LossesRecent quarterly revenue declines alongside increased operating losses reflect a structural gap between commercial income and expense base. Unless offset by new partnerships, cost reductions, or successful program readouts, this trend pressures runway and may force strategic, potentially dilutive, financing decisions.
ProQR News
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.07 and its highest was $3.10 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $153.80M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Feb 19, 2026 which is in 2 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Nov 06, 2025. The company reported -$0.119 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.001.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.12.
How many shares outstanding does ProQR have?
ProQR has 105,345,190 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.119 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in PRQR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (482.19% Upside)
$8.50 (482.19% Upside)
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.08%
12-Months-Change
Fundamentals
Return on Equity
-99.45%
Trailing 12-Months
Asset Growth
27.61%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
PRQR Stock 12 Month Forecast
Average Price Target
$8.50
▲(482.19% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.81% Mutual Funds
10.21% Other Institutional Investors
87.59% Public Companies and
Individual Investors